Hot Topics | Published:

Amyloid oligomer interactions and polymorphisms: disease-relevant distinct assembly of α-synuclein and tau

Neuropsychopharmacologyvolume 44pages222223 (2019) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Ahmed RM, Devenney EM, Irish M, Ittner A, Naismith S, Ittner LM, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2016;87:1234–41.

  2. 2.

    Gerson JE, Mudher A, Kayed R. Potential mechanisms and implications for the formation of tau oligomeric strains. Crit Rev Biochem Mol Biol. 2016;51:482–96.

  3. 3.

    Sengupta U, Guerrero-Munoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA, et al. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry. 2015;78:672–83.

  4. 4.

    Castillo-Carranza DL, Guerrero-Munoz MJ, Sengupta U, Gerson JE, Kayed R. alpha-Synuclein Oligomers Induce a Unique Toxic Tau Strain. Biol Psychiatry 2018;84:499–508.

  5. 5.

    Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134:187–205.

  6. 6.

    Guerrero-Munoz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen AA, Sengupta U, Lasagna-Reeves CA, et al. Amyloid-beta oligomers as a template for secondary amyloidosis in Alzheimer’s disease. Neurobiol Dis. 2014;71:14–23.

Download references

Acknowledgements

We thank all the members of Kayed laboratory for their helpful insights, suggestions and support. This work was supported by the Michael J. Fox foundation, the Gillson Longenbaugh Foundation, the Mitchell Center for Neurodegenerative Diseases, the Sealy Center for Vaccine Development and the NIH grants AG054025 (R.K.), NS094557 (R.K.) and AG055771 (R.K.).

Author information

Affiliations

  1. Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA

    • Urmi Sengupta
    •  & Rakez Kayed
  2. Departments of Neurology, Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA

    • Urmi Sengupta
    •  & Rakez Kayed

Authors

  1. Search for Urmi Sengupta in:

  2. Search for Rakez Kayed in:

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Rakez Kayed.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41386-018-0204-8